Chronic inflammation (inflammaging)
Inflammation is supposed to be a short, sharp emergency response that clears an infection and then shuts off; with age it stops shutting off, settling into a low, body-wide hum with no germ left to fight. This "inflammaging" ties heart disease, diabetes and dementia to a single shared mechanism — and it is unusually responsive to diet, exercise, sleep and stress.
Chronic inflammation, or inflammaging, is the eleventh of the twelve hallmarks of aging — an integrative hallmark, meaning it is less a root cause than a systemic consequence that then feeds back to accelerate everything upstream of it. Acute inflammation is one of the body's most useful tools: a self-limiting response that destroys pathogens, clears debris and triggers repair, then resolves. Inflammaging is what happens when that program never fully switches off — a sterile (germ-free), low-grade, persistent inflammatory state that pervades the tissues of older bodies and acts as both a symptom of aging and an active accelerant of it.[1]
How confident should you be
Descriptive — Strong. Measurement — Strong as prediction, Moderate as a target. Lifestyle intervention — Moderate. Drugs — Weak for healthy adults, none established; Moderate for preventing repeat heart attacks and strokes in people who already have heart disease.
This is one of the better-supported hallmarks. That inflammation rises with age in industrialised countries, that it comes from several converging sources, and that it predicts disease and death are all well established in large human cohorts — and unusually for this series, the headline finding rests on human data rather than mice. It may not be an inevitable part of ageing, though: when researchers applied a 19-cytokine inflammaging measure built in an Italian cohort to Amazonian forager-farmers and an Indigenous Malaysian population, the immune signals clustered differently, showed little or no rise with age and were not linked to age-related disease.[2] Measurement is a genuine strength: the markers are cheap, routine blood tests. Where confidence drops is causation and treatment. Most of the intervention evidence shows that behaviours which lower inflammatory markers also improve health, without establishing that the marker change is what did the work. And the pharmacological side is early for healthy people: one flagship longevity trial has never enrolled a participant and another missed its primary endpoint, while the only drugs that have cut hard outcomes by calming inflammation were tested in heart patients.
What makes it "sterile," and why that matters
Strong. Settled immunology.
The defining oddity of inflammaging is that there is nothing to fight. Classic inflammation is launched when the immune system detects a pathogen. Inflammaging is launched by the body's own damaged components — molecules released by stressed and dying cells that the immune system mistakes for an infection. These internal alarm signals are called damage-associated molecular patterns (DAMPs), and the master switch they flip is a transcription factor known as NF-κB (nuclear factor kappa B), which coordinates the cell's entire pro-inflammatory program.[3]
In a young body, NF-κB flares briefly and then resolves. In an aging body the upstream alarms never stop ringing, so it stays chronically switched on.[4] That persistent, purposeless activation is the heart of the problem — and because the signals travel in the bloodstream, a process that begins as scattered local damage becomes a body-wide inflammatory tone.
The sources all converge
Strong. Each source below is independently well characterised, though the gut contribution rests mainly on animal work; what remains uncertain is their relative contribution.
Inflammaging is not driven by one thing. It is the sum of several age-related failures that each pour the same inflammatory fuel into circulation, which is exactly why it sits at the integrative tier of the hallmarks framework.
- Zombie cells. Senescent cells — damaged cells that stop dividing but refuse to die — keep releasing a mix of inflammatory signals (the senescence-associated secretory phenotype, or SASP), and recent work shows they help drive the chronic inflammatory signalling of ageing.[5] The SASP inflames the surrounding tissue and can push healthy neighbours into senescence too; the full mechanism is covered under cellular senescence.
- Leaked mitochondrial DNA. As the cell's power plants (mitochondria) accumulate damage and are cleared too slowly, they spill their own DNA into the cell interior. Because that DNA structurally resembles bacterial DNA, sensors that evolved to detect infection read it as one and fire — a thread that also runs through genomic instability.[6]
- An aging immune system. With age, blood-cell production skews toward pro-inflammatory cell types, the thymus shrinks and stops making fresh naive immune cells, and the repertoire fills with exhausted T-cells that have lost their ability to clear pathogens but still pump out inflammatory signals. This immunosenescence both fuels inflammaging and is worsened by it.[7]
- Visceral fat. Fat stored around the organs is an active inflammatory organ. As it expands, its resident immune cells switch from an anti-inflammatory to a pro-inflammatory state and secrete signalling proteins — interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) among them — directly into the bloodstream.[8]
- A leakier gut, in some people. In animal studies the gut wall becomes leakier with age and lets bacterial fragments into the blood, where they keep prodding the immune system.[9] In people the picture is less clear: direct permeability tests found the barrier works about as well in healthy 65–75-year-olds as in young adults; among people with irritable bowel syndrome the older ones leaked more, in the small intestine rather than the colon,[10] and permeability was also higher in older people with inflammation together with type 2 diabetes.[11] This is the link to dysbiosis.
No single one of these explains inflammaging. Together they sustain it.
How systemic inflammation becomes disease
Moderate. The pathway is well worked out mechanistically and consistent with the epidemiology, but it is a mechanistic model rather than something a trial has tested end to end.
The reason inflammaging matters clinically is that it does not stay abstract — it converges on a shared pathway linking metabolic dysfunction, blood-vessel damage and brain decline. The hinge is insulin resistance and the health of the cells lining blood vessels, the endothelium.[12]
In a healthy vessel, insulin tells the cells lining it to make nitric oxide, which relaxes and widens arteries, keeps blood from clotting when it shouldn't, and calms inflammation. When those cells become insulin resistant, a state that typically comes with high blood sugar, excess blood fats and inflammation, the nitric-oxide arm of insulin signalling weakens while the arm that releases the vessel-tightening hormone endothelin-1 keeps working or even speeds up. Vessels lose their relaxant and tilt toward stiffness, higher blood pressure and inflamed artery walls where plaque builds.[13][14] That is the mechanistic bridge from a diffuse inflammatory state to the hard cardiovascular outcomes covered under cholesterol and blood pressure, and it is the common pathway that ties obesity, hypertension and atherosclerosis together.[15]
The same circulating signals reach the brain, and here the evidence is a working hypothesis rather than an established chain. The proposed sequence: inflammation loosens the blood-brain barrier (the seal that keeps blood contents out of brain tissue), inflammatory molecules leak in, the brain's own immune cells stay switched on, and brain cells become resistant to insulin, use glucose less well, and build up more of the amyloid and tau changes seen in Alzheimer's disease. Much of this comes from animal studies that do not all agree.[16] In people the support is mostly observational: long-running inflammatory conditions such as obesity, type 2 diabetes and rheumatoid arthritis are linked to faster cognitive decline and more dementia, though not every study agrees.[17] This shared inflammatory-metabolic root is why the same lifestyle pattern tends to protect heart, metabolism and brain at once — the territory of dementia prevention.
Measuring it
Strong as prediction; Moderate as a target. The markers are validated against mortality in large human cohorts — this is the best-evidenced claim on the page. What they cannot yet tell you is whether changing them changes your outcome.
Inflammaging can be tracked cheaply, which makes it one of the more actionable hallmarks. The everyday clinical markers are high-sensitivity C-reactive protein (hs-CRP) and interleukin-6, both inexpensive blood tests of baseline inflammatory tone. Both predict hard outcomes in large studies. Among 113,491 white Danish adults, the fifth with the highest CRP had about 70% higher risk of dying over follow-up than the lowest fifth.[18] Pooling 14 cohorts with 59,396 people, those in the top quarter for IL-6 had roughly 45% to 110% higher risk across nine heart and mortality outcomes than the bottom quarter, and IL-6 added a little predictive information beyond hs-CRP.[19] A third marker, essentially free, is the neutrophil-to-lymphocyte ratio, calculable from any standard blood count. In 8,715 Dutch adults (mean age 66) it was higher in older age groups and, over about 12 years, a higher ratio went with a higher risk of death even after accounting for other risk factors.[20] Because single markers are noisy, researchers increasingly combine several into composite scores, and have built "inflammatory clocks" such as iAge, which reads a panel of immune signals from a blood sample to estimate immune age; in its first study of 1,001 people aged 8 to 96 it tracked multiple illness, frailty and heart ageing.[21][22] Two of its developers co-founded a company that uses it.[23] The widely used epigenetic clock GrimAge has a second version that explicitly folds in a methylation-based estimate of C-reactive protein, tying epigenetic age directly to inflammatory status.[24]
The most striking finding in this area is how powerful a plain inflammation score turns out to be. In 3,113 adults in the US Health and Retirement Study (mean age 68), researchers built a composite of seven inflammatory markers — including the same neutrophil-to-lymphocyte ratio available on any blood count — and set it alongside thirteen DNA-methylation epigenetic clocks. The inflammation score tracked epigenetic age acceleration on ten of the thirteen, yet it still predicted four-year mortality after adjusting for them, implying it captures a distinct biological process. Taken on its own, it predicted four-year death slightly better than any of the six clocks it was compared with (a score of 0.68 against 0.66 for the best clocks, on a scale where 0.5 is a coin toss and 1 is perfect), and better than obesity or having several chronic diseases; only age itself did better (0.74). Once the usual risk factors were added, the inflammation model and the best clock models performed about the same.[25]
Inflammation markers also go hand in hand with frailty, the geriatric syndrome of depleted physiological reserve: among 800 hospitalised adults aged 60 and over, a higher neutrophil-to-lymphocyte ratio, CRP and related markers were linked to frailty independently of age and heart disease, though markers and frailty were measured at the same time and acute illness may have inflated the readings.[26] So a simple measure of how inflamed you are is a serious read on biological aging, but not a clear winner over the methylation clocks: in a 2026 cohort of 970 adults (median age 64), faster ageing on the iAge inflammatory clock was more weakly linked to lower physical and mental capacity than faster epigenetic ageing was, and people with both fared worst.[27] The two kinds of measure look complementary rather than rivals.
What a high reading cannot tell you is whether pushing the number down helps. CRP itself looks like a bystander rather than a cause: in genetic analyses, people carrying variants that raise their CRP did not die earlier.[28] And in heart patients the results are mixed: some anti-inflammatory drugs cut heart attacks and strokes, but in the largest colchicine trial the drug lowered CRP without reducing events (see the drug frontier below), and a 2025 American College of Cardiology statement, while calling the case for inflammation compelling, cautions that not all anti-inflammatory trials in heart patients have succeeded.[29] Treat a high reading as a warning about what is driving it, not as a number to push down for its own sake.
What actually lowers it
Diet — Moderate. Exercise — Moderate. Fasting schedules specifically — Weak. Stress and sleep — Weak.
This is where inflammaging is most encouraging: it responds to behaviour, and the levers are the familiar ones. A recurring lesson, though, is that the inflammatory benefit often tracks with weight loss and overall dietary quality rather than any single food or fasting schedule — so the honest framing is "patterns, not tricks."
An anti-inflammatory dietary pattern. Composite patterns beat isolated supplements. Of the named eating patterns, the Mediterranean diet has the most trial evidence: pooling 33 randomised trials with about 3,500 adults, it lowered high-sensitivity CRP and IL-6 compared with control diets, although not every marker moved (TNF-α did not).[30] An earlier pooling of 22 trials found clear drops only in IL-6 and IL-1β, with CRP falling by about 1 mg/L but not reliably.[31] The DASH diet (Dietary Approaches to Stop Hypertension) has far fewer trials, but in those it lowered high-sensitivity CRP by about 1 mg/L compared with a usual diet, and did neither better nor worse than other healthy diets.[32] The fair reading is that a whole-food, plant-heavy pattern helps, and the Mediterranean version is simply the best tested, not proven superior. The practical version is the Mediterranean dietary pattern, and avoiding the pro-inflammatory drivers covered under ultra-processed food.[33]
Two mechanisms inside that pattern are worth singling out. The marine omega-3 fats EPA and DHA (eicosapentaenoic and docosahexaenoic acid) do more than dampen inflammation — they are the raw material the body uses to build specialized pro-resolving mediators, signalling molecules that actively switch inflammation off and orchestrate clean-up rather than merely blocking it.[34] (Dosing is covered under omega-3.) And dietary fibre feeds gut bacteria that ferment it into short-chain fatty acids, chiefly butyrate, which both calm immune signalling and serve as the primary fuel for the cells of the gut lining — shoring up the gut barrier, which can leak bacterial fragments into the blood when it weakens.[35] Fermented foods support the same axis.
In practice, though, a fish-oil capsule does little to the blood markers of healthy people: in the VITAL trial, 1 g a day of marine omega-3 for four years did not change CRP, IL-6 or TNF-α in about 1,000 adults averaging 65 years old.[36] Drops in CRP show up mainly in people who already have heart disease, high blood pressure or metabolic syndrome, at intakes up to about 1.2 g of EPA plus DHA a day, and not in people who are simply overweight.[37] Fibre does a little better on the markers: in trials in adults with overweight or obesity, eating about 8 g a day more fibre lowered CRP slightly, by roughly 0.4 mg/L, an effect that only just reached statistical significance.[38]
Caloric restriction — with an honest caveat on fasting. Sustained moderate calorie restriction has the best evidence. In the two-year CALERIE trial, healthy adults of normal or slightly high weight who ate about 12% less than usual lost about 10% of their body weight. C-reactive protein fell by more than a third, and TNF-α fell more than in the control group by the end of year two. Quality of life did not suffer. There were trade-offs: active thyroid hormone (T3) dropped, bone density at the spine and hip fell slightly more than in controls, and a few participants had to pause for anaemia.[39] A 2026 analysis of stored CALERIE blood samples points to one way it works: calorie restriction (about 14% fewer calories on average over two years) damped the complement system, an arm of innate immunity whose activation fragment C3a rises with age in both people and mice and appears to come mainly from a group of immune cells that builds up in belly fat; blocking that fragment inside fat tissue reduced age-related inflammation in mice.[40] The story for intermittent fasting is more equivocal: a 12-month randomised trial in 90 adults with obesity found that time-restricted eating and standard calorie restriction each took off only 4–5% of body weight, and neither lowered CRP, IL-6 or TNF-α compared with a control group by month 12, though the authors note the trial was probably too small to detect changes in these markers.[41] Pooled studies point the same way: time-restricted eating did not lower CRP or IL-6, with at most a small dip in TNF-α,[42] and in people with overweight or obesity, ordinary calorie restriction lowered CRP and IL-6 while intermittent fasting moved only TNF-α, though there were far fewer fasting trials, and the reviewers had concerns about how some of the included trials were randomised.[43] An earlier review of alternate-day fasting found CRP fell only in trials where people lost more than about 6% of their body weight.[44] The takeaway: the energy deficit and the fat loss are doing most of the work, not the clock.
Exercise — and the IL-6 paradox. This is the most counter-intuitive piece of the puzzle. Interleukin-6 is usually a villain of inflammaging, yet working muscle releases a burst of it into the blood during exercise, and this muscle-derived IL-6 behaves differently. During exercise it signals mainly through receptors found on a small number of cell types, not the receptor-hitching route (trans-signalling) that drives IL-6's inflammatory effects in disease.[45] When healthy volunteers were given IL-6 at the level seen in hard exercise, their blood levels of two anti-inflammatory signals, IL-1 receptor antagonist (IL-1ra) and IL-10, rose, and TNF-α did not.[46] Over time, regular training lowers baseline inflammation: it turns down the infection-sensing receptors on circulating immune cells, fewer inflammatory immune cells move into tissues such as fat, and macrophages shift toward a tissue-repairing state.[47] Trials back this up. Pooling 49 randomised trials in people averaging 65 or older (about 1,900 participants), exercise training produced a small-to-moderate drop in CRP and smaller drops in TNF-α and IL-6, with the clearest gains in people who already had a chronic disease.[48] A 2026 analysis ranking training types across 55 trials in healthy middle-aged and older adults put strength training first for lowering CRP and aerobic training first for IL-6 and TNF-α, which argues for doing some of each.[49] The dose-response is hormetic, though. After a long, exhausting endurance effort, inflammatory signals stay raised for about a day and immune defences can dip for anywhere from 3 to 72 hours, though how much that dip matters for athletes is still debated. Repeated hard bouts without recovery can keep inflammation raised, which is why recovery is part of the prescription, not an afterthought.[50] The site covers practical dosing under zone 2, VO₂ max and resistance training.
Stress and sleep. Chronic psychological stress keeps the stress-hormone system switched on, and over time immune cells can stop responding to cortisol's normal calming signal. In healthy volunteers deliberately exposed to a cold virus, people facing a long-running stressful situation showed this resistance, and those with it were more likely to catch the cold and produced more inflammatory signals once infected. That removes one of the body's brakes on inflammation.[51] Mindfulness-based stress reduction, the standard eight-week program of body-scan meditation, sitting meditation and mindful movement, has only modest evidence behind it. In a review of 20 randomised trials, CRP fell clearly in just one of the six trials that measured it, two more showed a trend, and other inflammatory signals such as IL-6 and TNF-α did not reliably change; the authors call the findings tentative and note large differences between studies.[52] A later preregistered meta-analysis of 32 trials of mindfulness-based programs found at most a small effect on inflammation and stress markers, one that only just missed statistical significance, and warned that weak studies and selective publishing may have biased the results.[53] Two other poolings lean more positive: across 45 randomised trials against an active comparison, meditation lowered CRP and TNF-α,[54] and across 48 randomised trials of mindfulness programmes, CRP and IL-6 fell slightly by the end of the programme.[55] A 2025 analysis reported larger drops in CRP and IL-6 in randomised trials, but drew its overall conclusion from a pool that also included studies with no control group and unpublished dissertations.[56] Sleep matters too, though the link is modest. Pooled data from more than 50,000 people show that those with disturbed sleep, and those who sleep very long hours, have slightly higher CRP and IL-6, while short-term sleep loss in the lab does not reliably raise them.[57] In a randomised trial in 123 older adults with insomnia, four months of cognitive behavioural therapy for insomnia (CBT-I) lowered CRP compared with a sleep-education class, and the drop was still there 16 months later.[58] The broader picture lives under stress and recovery, and the direct sleep-and-senescence experiment under cellular senescence.
The drug frontier
Weak for healthy adults; Moderate in people with heart disease. None of the longevity drugs further down (metformin, rapamycin, senolytics) is established for healthy adults; they are covered in depth under geroprotectors. The one place drugs that calm inflammation have cut hard outcomes is cardiology, covered first.
- Colchicine and canakinumab — proof of principle, in heart patients only. The clearest evidence that calming inflammation itself can prevent disease comes from cardiology, not longevity research. In the CANTOS trial, about 10,000 people who had already had a heart attack and still had a raised CRP (2 mg/L or more) were given canakinumab, an antibody that blocks the inflammatory signal IL-1β. At the 150 mg dose, repeat heart attacks, strokes and cardiovascular deaths were about 15% lower, with no change in cholesterol. Fatal infections were more common, though, and overall deaths did not fall.[59] Low-dose colchicine (0.5 mg a day), an old and cheap gout drug, did something similar. Among 5,522 people with stable coronary disease, events fell from 9.6% to 6.8% over about two and a half years, about 31% fewer.[60] Started within a month of a heart attack, it took events from 7.1% to 5.5%.[61] But the largest colchicine trial, CLEAR, started the drug right after a heart attack in 7,062 people and found no benefit over three years (9.1% vs 9.3%), even though CRP fell.[62] Pooled across six trials and 21,774 patients, colchicine still cut major cardiovascular events by about a quarter, though it had no clear effect on deaths from heart disease.[63] In the US, low-dose colchicine is now approved to prevent heart attack and stroke in adults with established atherosclerosis or several cardiovascular risk factors.[64] Blocking IL-6 directly is the next test: the antibody ziltivekimab is being tried in 6,376 people with atherosclerosis, kidney disease and a raised CRP, with results still to come,[65] though its trial in a common form of heart failure was stopped early because it was not working.[66] None of these trials enrolled healthy people, and none tested whether the drugs slow aging.
- GLP-1 drugs lower inflammation too. In the SELECT trial of adults with heart disease and overweight but no diabetes, weekly semaglutide cut CRP by about 38% over two years. The fall began within weeks, before most of the weight came off, and even showed up in people who lost no weight.[67] The drug cut major cardiovascular events by 20%, and modelling suggests the lower inflammation may explain part of that benefit,[68] but the estimates are too imprecise to say how much.[69]
- Metformin, the long-standing diabetes drug, activates the cell's low-fuel sensor — the enzyme that switches on when energy runs short — and dampens NF-κB-driven inflammation.[70] The large TAME trial (Targeting Aging with Metformin) was designed to test it for broad age-related disease prevention in non-diabetic older adults aged 65 to 79, partly to establish "aging" as a treatable indication with regulators.[71] It has never been fully funded: the US National Institute on Aging set aside about $5 million against an estimated cost of $45–70 million, and the rest still depends on donors.[72] As of late 2026 it is not registered on ClinicalTrials.gov and has enrolled nobody — still a proposal waiting for money, not a study in progress.
- Rapamycin blocks mTOR, the master nutrient-sensing pathway discussed under deregulated nutrient sensing, and in cell and mouse studies this damps down much of the inflammatory secretion of senescent cells.[73] People using it for longevity usually take low weekly doses rather than the daily doses used after transplants, aiming to avoid immune suppression. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) — 114 healthy adults, 48 weeks, randomised and placebo-controlled — is the best human evidence, and it should be read carefully: its primary outcome, a reduction in visceral fat, did not move at all (p = 0.942), and blood biomarkers stayed within normal ranges. Women on the higher weekly dose did gain lean tissue and report less pain, but that arm held only 8 women, so this is a hint rather than a finding, and the drug was well tolerated apart from more stomach upset. The results count only the 114 people who finished (11 of 125 dropped out), and its authors are employees or shareholders of AgelessRx, a company that prescribes rapamycin for longevity. One further caveat sits inside the trial: independent testing found the compounded rapamycin it used carried only about a third the bioavailability of generic sirolimus, so participants received meaningfully less drug than the labels implied.[74]
- Senolytics and senomorphics attack the SASP at its source, by clearing senescent cells or silencing their secretions. The human evidence — and the real cautions, including a small uncontrolled pilot in which 19 adults aged roughly 43 to 87 took the popular dasatinib-plus-quercetin combination for six months and several older-style epigenetic clocks read older, not younger, while the newer GrimAge and DunedinPACE clocks did not move[75] — is laid out under cellular senescence.[76]
What this does and doesn't tell you
What it tells you: inflammaging is a real, measurable and consequential process — the convergence point where senescent cells, leaked mitochondrial DNA, an aging immune system, visceral fat and, in some people, a leakier gut all feed a single body-wide inflammatory state that drives cardiovascular and metabolic disease and is thought to feed neurodegeneration. It is trackable with cheap blood tests, and in more than three thousand older adults a plain seven-marker inflammation score predicted four-year mortality about as well as, or slightly better than, the six epigenetic clocks it was compared with. Most importantly, it responds to ordinary levers. A Mediterranean-pattern diet, sustained calorie restriction and regular well-recovered exercise have measurably lowered inflammatory markers in trials, and treating insomnia lowered CRP in one trial; extra fibre has a small effect, while fish oil in healthy people and mindfulness training have shown little reliable change in the markers.
What it doesn't tell you: that any drug or supplement should be used to suppress inflammation for longevity in a healthy person. The pharmacological agents are promising but unproven for that purpose — TAME has never enrolled anyone, and PEARL missed its primary endpoint. It also does not tell you that lowering a marker lowers your risk. The lifestyle evidence shows behaviours moving markers, not markers moving outcomes. The stronger claim has only been tested in people who already have heart disease. There, drugs that target inflammation rather than cholesterol have cut heart attacks, strokes and related cardiac events by roughly 15 to 30% in some trials,[77][78] but one of them brought more fatal infections, the largest colchicine trial after a recent heart attack found no benefit even though CRP fell,[79] and none of this has been tested in healthy adults. Fasting's anti-inflammatory effect appears to ride mostly on fat loss rather than the schedule itself. And inflammation is not simply "bad" — the acute, resolving kind is essential, and the goal is to restore its off-switch, not to abolish it. As with the other hallmarks, the elegance of the mechanism runs well ahead of the proven interventions, and the proven interventions are the unglamorous ones.
Further reading
- Karpuzoglu E, et al. Inflammaging: triggers, molecular mechanisms, immunological consequences, sex differences, and cutaneous manifestations. Front Immunol 2025.[80]
- Müller L, et al. Immunosenescence and inflammaging: Mechanisms and modulation through diet and lifestyle. Front Immunol 2025.[81]
- Cielecka J, Szkamruk Z, et al. From Metabolism to Mind: The Cardio–Metabolic–Brain Axis and the Role of Insulin Resistance—A Review. Biomedicines 2026.[82]
- Meier HCS, et al. Systemic inflammation and biological aging in the Health and Retirement Study. GeroScience 2023 — n=3,113; on its own the seven-marker score slightly out-predicted the six clocks it was compared with for four-year mortality, a near tie once other risk factors were added.[83]
- Gaylord A, et al. Biomarkers of aging through the life course: A Recent Literature Update. Curr Opin Epidemiol Public Health 2023.[84]
- Wu F, Mu WC, et al. Immunological biomarkers of aging. J Immunol 2025.[85]
- Koelman L, et al. Effects of Dietary Patterns on Biomarkers of Inflammation and Immune Responses: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr 2022.[86]
- Ravussin E, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. J Gerontol A Biol Sci Med Sci 2015 — CALERIE Phase 2.[87]
- Lin S, et al. Time-Restricted Eating Versus Daily Calorie Restriction: Effects on Inflammatory Markers over 12 Months in Adults with Obesity. Nutrients 2025.[88]
- Mulas A, Cienfuegos S, et al. Effect of intermittent fasting on circulating inflammatory markers in obesity: A review of human trials. Front Nutr 2023.[89]
- Shi X, Hu L, et al. Exercise workload: a key determinant of immune health — a narrative review. Front Immunol 2025.[90]
- Black DS, Slavich GM. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci 2016.[91]
- Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025 — n=114; primary outcome null.[92]
- Rehman A, et al. Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer. Cancers (Basel) 2025.[93]
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab 2016 — the TAME rationale.[94]